Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
| ▸ | BCR | P11274 | 1/20 | 0.83 |
| ▸ | CLK1 | P49759 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.72 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772489 | 1.00 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL2230377 | 0.91 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL31060426 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL370573 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| Methane SCHEMBL22343918 | 0.86 | FLT3 (0.96) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL31060211 | 0.82 | FLT3 (1.00) | FLT3PDGFRBPDGFRA | |
| SCHEMBL20742916 | 0.82 | FLT3 (0.81) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL61386 | 0.79 | SMAD3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL6865103 | 0.78 | FLT3 (1.00) | FLT3PDGFRBPDGFRA | |
| SCHEMBL2732420 | 0.77 | FLT3 (0.73) | FLT3PDGFRBPDGFRAKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | claimed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | claimed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | claimed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | claimed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | VITRISA THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3414330-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | Vitrisa Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | SILICON VALLEY BANK | 2018-11-29 | — | — | US | disclosed |
| WO-2018148333-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | VITRISA THERAPEUTICS, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180340179-A1 | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF-LIFE AND USES THEREOF | UACA, CRYAA, CRYAB | FLT3 3416/4885PDGFRB 1282/4885PDGFRA 1584/4885 |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | FLT3 526/4885PDGFRB 2508/4885PDGFRA 2125/4885 |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | FLT3 230/4885PDGFRB 474/4885PDGFRA 542/4885 |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | UACA, CRYAA, CRYAB | FLT3 3416/4885PDGFRB 1282/4885PDGFRA 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.